Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil

INTRODUCTION: Benznidazole is used for treating Chagas disease (CD). This cross-sectional study aimed to characterize the adverse drug reactions (ADRs) of benznidazole at a public hospital in Brazil’s Federal District. METHODS: Medical records were analyzed and ADRs were categorized by type, intensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gontijo, Maria Katarine Costa Lucas, de Arruda, Hilda Maria Benevides da Silva, Noronha, Elza Ferreira, de Toledo, Maria Inês
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Medicina Tropical - SBMT 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083386/
https://www.ncbi.nlm.nih.gov/pubmed/31994658
http://dx.doi.org/10.1590/0037-8682-0150-2019
Descripción
Sumario:INTRODUCTION: Benznidazole is used for treating Chagas disease (CD). This cross-sectional study aimed to characterize the adverse drug reactions (ADRs) of benznidazole at a public hospital in Brazil’s Federal District. METHODS: Medical records were analyzed and ADRs were categorized by type, intensity, seriousness, and causality. RESULTS: Of the 62 patients who started benznidazole treatment for CD, 41 (66%) presented with 105 ADRs; 23 (37%) discontinued the treatment. Most reactions were classified as probable (81%), severe (63%), serious (67%), and dose-dependent (56%). CONCLUSIONS: The high incidence of ADRs because of treatment withdrawal revealed the need for safer alternatives for CD treatment.

Ejemplares similares